Why Upstream Bio, Inc.’s (UPB) Stock Is Down 12.03%
As of Thursday, November 05, Upstream Bio, Inc.’s UPB share price has dipped by 12.03%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Upstream Bio, Inc.’s (UPB) Stock Is Down 6.74%
As of Monday, November 02, Upstream Bio, Inc.’s UPB share price has dipped by 6.74%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Upstream Bio, Inc.’s (UPB) Stock Is Up 5.54%
As of Thursday, October 29, Upstream Bio, Inc.’s UPB share price has surged by 5.54%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Upstream Bio, Inc.’s (UPB) Stock Is Up 6.57%
As of Monday, October 26, Upstream Bio, Inc.’s UPB share price has surged by 6.57%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Upstream Bio, Inc.’s (UPB) Stock Is Down 5.69%
As of Friday, October 23, Upstream Bio, Inc.’s UPB share price has dipped by 5.69%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | UPB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $175.8 | $214.3 | 27% |
|
| Shares Out (Mil) | 54.6 | 53.9 | 49% |
|
| Institutional Ownership | 99.9% | 92.9% | 96% |
|
| Float (Mil) | 42.8 | 41.4 | 43% |
|
| Beta | na | 0.96 | na |
|
| Avg Daily Volume (000s) | 1,089 | 506 | 70% |
|
| Price Change (52-week) |
(87.2%) | 43.9% | 6% |
|
| Growth | UPB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 7 | |
| Current EPS | ($0.729) | ($2.903) | ($2.801) | |
| Month Ago EPS | ($0.729) | ($2.903) | ($2.801) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 3 | 1 | |
| Three Months Ago EPS | ($0.698) | ($2.841) | ($2.888) | |
| Year/Year Chg | 0.1% | 9.0% | 10.3% | |
| Financials | UPB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3 | $37 | 4% |
|
| Net Income (TTM) (Mil) | ($157) | ($44) | 8% |
|
| EPS (TTM) | ($2.886) | ($1.500) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($136) | ($34) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $34 | $1 | 67% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 12% |
|
| Enterprise Value (Q1) (Mil) | $34 | $172 | 14% |
|
| Valuation | UPB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.65 | 2.00 | 15% |
|
| P/E | na | 18.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | UPB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 67.3% | 96% |
|
| Net Margin | na | (63.5%) | na |
|
| ROA | (44.6%) | (47.5%) | 12% |
|
| ROE | (46.0%) | (53.3%) | 16% |
|
| Liabilities to Assets | 3.6% | 29.6% | 2% |
|
| F-Score | 4 | 2 | 33% |
|
Upstream Bio, Inc. did not pass any screens on 11/5/2026.
